Feedlot performance of steers treated concurrently with ceftiofur crystalline-free acid subcutaneously in the posterior aspect of the ear and a growth-promoting implant.
Ceftiofur crystalline-free acid sterile suspension (CCFA-SS), a long-acting formulation of ceftiofur formulated for subcutaneous injection in the middle third of the posterior aspect of the ear, is being developed for the control and treatment of bovine respiratory disease. A study was designed to evaluate average daily gain (ADG) and feed efficiency (FE) for cattle through 140 days in the feedlot after CCFA-SS was administered concurrently in the same ear with a growth-promoting implant. On Day 0, steers (n = 207) averaging 189 kg in weight were randomly assigned to the following treatments: Revalor -S implant (120 mg trenbolone acetate and 24 mg estradiol per implant; Hoechst-Roussel Agri-Vet Company) (n = 64); CCFA-SS at 6.6 mg ceftiofur equivalents/kg and a Revalor -S implant (n = 64); untreated control (no CCFA-SS or implant) (n = 63); or CCFA-SS only (n = 16). On Day 56, an Implus-S implant (200 mg progesterone USP plus 20 mg estradiol benzoate; Pharmacia and Upjohn Animal Health) was administered to all cattle. Tolerance of administration of all materials was observed visually and by palpation of the treated ears. Average daily gain and FE from Day 0 through Day 56 were significantly (P <.001) better for steers of both groups with an implanted growth-promotant than for untreated controls. From Day 0 through Day 140, ADG was significantly (P <.05) better for cattle given an implant or an implant plus CCFA-SS than for untreated controls and FE was significantly (P <.05) better for cattle given an implant plus CCFA-SS than for controls. Mild or moderate, transient swelling of the treated ear was observed in two cattle (CCFA-SS plus implant) on Day 52. On Day 56, 88 % of cattle treated with CCFA-SS, 84 % of the cattle treated with an implant plus CCFA-SS, and 100 % of cattle in other groups were normal. Administration of CCFA-SS in the middle third of the posterior aspect of the ear at the same time as growth-promoting implants did not affect performance of cattle in the feedlot and was well tolerated by the animals.
Hibbard
Beth
B
Pharmacia Animal Health, Kalamazoo, MI 49001, USA.
Robb
Edward J
EJ
Apley
Michael D
MD
Chester
S Theodore
ST
Dame
Kenneth J
KJ
D000821:Animal Feed; D000818:Animals; D002417:Cattle / Q000254:growth & development / Q000502:physiology*; D002418:Cattle Diseases / Q000517:prevention & control; D002511:Cephalosporins / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D004338:Drug Combinations; D004343:Drug Implants / Q000009:adverse effects / Q000494:pharmacology*; D004347:Drug Interactions; D004423:Ear; D004958:Estradiol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D007279:Injections, Subcutaneous; D008297:Male; D013997:Time Factors; D014204:Trenbolone Acetate / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology*; D015430:Weight Gain / Q000187:drug effects*
D002511:Cephalosporins; D004338:Drug Combinations; D004343:Drug Implants; C021828:Revalor; D004958:Estradiol; C053503:ceftiofur; D014204:Trenbolone Acetate